iShares Biotechnology ETF
843 hedge funds and large institutions have $5.12B invested in iShares Biotechnology ETF in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 204 increasing their positions, 312 reducing their positions, and 65 closing their positions.
0.41% less ownership
Funds ownership: 65.97% → 65.56% (-0.41%)
0% less call options, than puts
Call options by funds: $233M | Put options by funds: $234M
4% less capital invested
Capital invested by funds: $5.31B → $5.12B (-$196M)
3% less funds holding
Funds holding: 866 → 843 (-23)
21% less funds holding in top 10
Funds holding in top 10: 14 → 11 (-3)
23% less first-time investments, than exits
New positions opened: 50 | Existing positions closed: 65
35% less repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 312
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$47.9M |
| 2 |
Citigroup
New York
|
+$46M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$32M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$23.6M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$93.5M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$68.1M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$36.4M |
| 4 |
HMH
Hackensack Meridian Health
Edison,
New Jersey
|
-$29.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$18.8M |
IBB Hedge Fund Activity: Q2 2023 in Review
843 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q2 2023, worth a combined $5.12B — down 3.7% from $5.31B a quarter earlier.
Sellers outnumbered buyers: 65 funds closed out of IBB and 50 opened new positions — a net loss of 15 holders — while 312 trimmed existing stakes and 204 added.
The largest buyer was Millennium Management, adding an estimated $47.9M. The largest seller was Goldman Sachs, cutting an estimated $93.5M.
- 843 institutional investors held iShares Biotechnology ETF (IBB) as of Q2 2023, down from 866 in Q1 2023.
- Funds reported $5.12B of iShares Biotechnology ETF stock for Q2 2023, down 3.7% quarter-over-quarter.
- 50 funds opened new iShares Biotechnology ETF positions in Q2 2023 and 65 closed out, a net change of -15 holders.
- The largest iShares Biotechnology ETF buyer in Q2 2023 was Millennium Management, an estimated $47.9M added.
- The largest iShares Biotechnology ETF seller in Q2 2023 was Goldman Sachs, an estimated $93.5M sold.
Based on aggregated 13F filings for Q2 2023.